Blau Farmacêutica S.A. (BVMF:BLAU3)

Market Cap	2.43B +0.1%
Revenue (ttm)	1.79B +1.1%
Net Income	233.83M -17.3%
EPS	1.01 -17.1%
Shares Out	230.98M
PE Ratio	10.44
Forward PE	7.90
Dividend	0.36 (3.32%)
Ex-Dividend Date	Sep 30, 2026

Volume	277,800
Open	10.50
Previous Close	10.51
Day's Range	10.39 - 10.73
52-Week Range	8.28 - 11.84
Beta	0.47
Analysts	Hold
Price Target	11.68 (+9.06%)
Est. Earnings	Nov 6, 2026

About Blau Farmacêutica

Blau Farmacêutica S.A., a pharmaceutical company provides drug products in Brazil, Argentina, Chile, Colombia, Uruguay, Ecuador, Peru, and the United States. Its products cover various areas, such as immunology, hematology, oncology, nephrology, infectology, and anesthesiology. The company offers uterine stimulator, antirheumatic, anaesthetics, antibiotics, feminine health care, biopharmaceuticals, oncologicals, hospital products, antivirals and antiretrovirals, biológicos, acid pump inhibitor, hemoderivatives, antithrombotic, and thrombolytics...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1987
• Employees: 1,900
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: BLAU3

Financial Performance

In 2025, Blau Farmacêutica's revenue was 1.70 billion, a decrease of -2.96% compared to the previous year's 1.75 billion. Earnings were 294.96 million, an increase of 35.80%.

Analyst Summary

According to 12 analysts, the average rating for BLAU3 stock is "Hold." The 12-month stock price target is R$11.68, which is an increase of 9.06% from the latest price.

Price Target

R$11.68

(9.06% upside)

Analyst Consensus: Hold

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 30, 2026

Data Sources Report a data error